Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04687358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Study acronym: RESONANCE
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Feb 2026 to Mar 2029v16
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 32 to 29
    v15
  3. Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd. to Kiniksa Pharmaceuticals International, plc
    • Site details revised at 3 of 32 sites
    • Collaborators expanded, about 4 words
    v14
  4. Study sites: 23 to 32v13
  5. Study sites: 22 to 23v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 17 to 22v11
  2. Study sites: 16 to 17v10
  3. Study sites: 15 to 16v9
  4. Study sites: 11 to 15v8
  5. Study sites: 6 to 11v7
  6. Study sites: 4 to 6v6
  7. Study sites: 1 to 4v5
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2021 to Mar 16, 2021
    v4
  9. Lead sponsor: Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals (UK), Ltd.v3
  10. Start date: Feb 2021 to Mar 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Trial Details
NCT Number NCT04687358
Lead Sponsor Kiniksa Pharmaceuticals International, plc
Collaborators: Kiniksa Pharmaceuticals (UK), Ltd.
Conditions
(from sponsor)		 Recurrent Pericarditis
Related terms Pericarditis
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov